Home > Boards > US Listed > Biotechs > Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals, Inc. (the “Company”) today announced that

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 572
Posts 36,798
Boards Moderated 6
Alias Born 12/12/04
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/9/2019 4:20:59 PM
Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Or... GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/30/2019 11:14:11 AM
Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS... GlobeNewswire Inc. - 9/30/2019 10:30:00 AM
Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Pr... GlobeNewswire Inc. - 9/10/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 5:05:56 PM
Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruv... GlobeNewswire Inc. - 9/4/2019 5:00:00 PM
Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019 GlobeNewswire Inc. - 8/29/2019 4:05:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/1/2019 8:57:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 7:29:52 AM
Agios Reports Business Highlights and Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/1/2019 7:00:00 AM
Agios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019 GlobeNewswire Inc. - 7/18/2019 7:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 7/16/2019 12:43:38 PM
Agios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International GlobeNewswire Inc. - 7/1/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/14/2019 4:22:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 4:08:48 PM
Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 GlobeNewswire Inc. - 6/10/2019 1:12:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/5/2019 4:09:33 PM
Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019 GlobeNewswire Inc. - 6/5/2019 4:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2019 4:03:11 PM
Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant... GlobeNewswire Inc. - 6/3/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:10:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:10:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:09:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:08:10 PM
crudeoil24 Member Level  Wednesday, 09/07/16 08:41:41 AM
Re: None
Post # of 47 
Agios Pharmaceuticals, Inc. (the “Company”) today announced that its collaboration partner Celgene Corporation (“Celgene”) expects to submit a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for enasidenib (AG-221), a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (“IDH2”), in relapsed and/or refractory acute myeloid leukemia (“AML”). The NDA will be based on data from the ongoing phase 1/2 study of AG-221 in patients with advanced hematologic malignancies with an IDH2 mutation. The NDA submission is expected to occur by year-end 2016. Celgene will be discussing the planned enasidenib NDA submission at the Citi 11th Annual Biotech Conference in Boston in a webcast event on Wednesday, September 7, 2016 at 12:00 pm ET.

DUKE BASKETBALL and NOTRE DAME FOOTBALL
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist